AstraZeneca Reaffirms Commitment To Patient Safety Amid Covid-19 Vaccine Concerns

In the wake of concerns surrounding potential rare side effects of the AstraZeneca-Oxford Covid-19 vaccine, the commitment to patient safety has been reaffirmed by the UK-headquartered pharmaceutical giant.

A spokesperson of AstraZeneca was quoted by news agency ANI as saying, "Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and clear and stringent standards are enforced by regulatory authorities to ensure the safe use of all medicines, including vaccines."

Photo Credit: PTI

The development comes as AstraZeneca acknowledged that a blood clot-related side effect can occur in "very rare cases" with its COVID-19 vaccine, although the causal link remains unknown, according to court papers cited in the UK media, as reported by India Today.

In a legal document submitted to the High Court in London in February for a group action brought by 51 claimants, it was admitted by AstraZeneca that the vaccine developed with the University of Oxford to protect against Covid-19 may cause Thrombosis with Thrombocytopenia Syndrome (TTS) in "very rare cases", as reported by The Daily Telegraph.

The AstraZeneca Vaxzevria vaccine, also produced by the Serum Institute of India, was marketed in India as Covishield. Notably in 2023, it was reported by the World Health Organisation (WHO) in its report that TTS emerged as a new adverse event following immunisation in individuals vaccinated with Covid-19 non-replicant adenovirus vector-based vaccines, as reported by India Today.

"TTS is a serious and life-threatening adverse event. This interim emergency guidance has been issued by WHO to increase awareness about TTS in the context of Covid-19 vaccination and assist healthcare providers in the assessment and management of potential TTS cases," read the 2023 statement by WHO.